952-27-2

Basic information

• Product Name: 2H-Pyrrole-2-carboxylic acid, 3,4-dihydro-5-phenyl-, ethyl ester
• CAS NO: 952-27-2
• Molecular Formula: C13H15NO2
• Molecular Weight: 217.268
• Mol File: 952-27-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2H-Pyrrole-2-carboxylic acid, 3,4-dihydro-5-phenyl-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-Pyrrole-2-carboxylic acid, 3,4-dihydro-5-phenyl-, ethyl ester(952-27-2)
• EPA Substance Registry System: 2H-Pyrrole-2-carboxylic acid, 3,4-dihydro-5-phenyl-, ethyl ester(952-27-2)

Safety Data

• Hazardous Substances Data: 952-27-2(Hazardous Substances Data)

Upstream product

• 69555-14-2 ethyl N-diphenylmethylene glycine 
• 768-03-6 Phenyl vinyl ketone 
• 540-63-6 ethane-1,2-dithiol 
• 1056469-57-8 ethyl (2R)-2-{[(tert-butoxy)carbonyl]amino}-5-oxo-5-phenylpentanoate 
• 94-38-2 3-diethylamino-1-phenyl-propan-1-one 
• 91958-55-3 ethyl 2-nitro-5-oxo-5-phenylpentanoate 

Downstream Products

• 212265-35-5 ethyl 2-phenyl-5-(prop-2'-en-1'-yl)-1-pyrroline-5-carboxylate 
• 212265-39-9 ethyl 5-(4'-methylpent-3'-en-1'-yl)-2-phenyl-1-pyrroline-5-carboxylate 

Relevant articles and documents

Enantioselective Copper-Catalyzed Electrophilic Sulfenylation of Cyclic Imino Esters

Herein we report an enantioselective sulfenylation of cyclic imino esters with the efficient and versatile sulfenylation reagent S-alkyl 4-methylbenzenesulfonothioates. By utilizing the Cu/tBu-Phosferrox catalytic system, we can assemble diverse S-alkyl groups into the cyclic imino esters under mild conditions in good yields and with excellent enantioselectivities. Remarkably, this method demonstrates a high tolerance of diverse functional groups and proves to be applicable in the late-stage functionalization of pharmaceuticals.

HIV integrase inhibitors

Nitrogen-containing heteroaryl dioxo-butyric acid derivatives are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.